This contract expires in 108 days (Oct 24, 2026).
UCB, INC - ZILBRYSQ 32.4MG/0.81ML INJ,SOLN SY.
Key Details
Description
ZILBRYSQ 32.4MG/0.81ML INJ,SOLN SY.
Context & Analysis
On Oct 7, 2025, Department of Veterans Affairs obligated $367,225.68 to UCB, INC for zilbrysq 32.4mg/0.81ml inj,soln sy.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in PITTSBURGH, PA. The contract is scheduled through Oct 24, 2026 — approximately 4 months remaining. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.